2009;107:144, 146-7. [19810379] 3 Brown AE, Ross DA, Simpson AJ, Erskine RS, Murphy G, Parry JV, Gill ON. Prevalence of markers for HIV, hepatitis B and hepatitis C infection in UK military recruits. Epidemiol Infect 2011;139:1166-71. [21208514] [http://dx.doi.org/10.10 17/S0950268810002712] 4 Keramat F, Eini P, Majzoobi MM. Seroprevalence of HIV, HBV and HCV in Persons Referred to Hamadan Behavioral Counseling Center,West of Iran. Iran Red Crescent Med J 2011;13:42-6. 5 Azarkar Z, Sharifzadeh G. Evaluation of the Prevalence of Hepatitis B, Hepatitis C, and HIV in Inmates with Drug-Related Convictions in Birjand, Iran in 2008. Hepat Mon 2010; 10:26-30. 6 Saleh-Gargari S, Hantoushzadeh S, Zendehdel N, Jamal A, Aghdam H. The Association of Maternal HBsAg Carrier Status and Perinatal Outcome. Hepat Mon 2009;9:180-4. 7 Hajiani E, Hashemi S, Masjedizadeh A. Seroepidemiology of Hepatitis B Virus Infection in Khuzestan Province, Southwest of Iran. Hepat Mon 2009; 9:34-8. 8 Singh AE, Wong T. Background document: HIV and hepatitis B co- infection. Department of HIV/AIDS, World Health Organization, 2009. 9 Nguyen CH, Ishizaki A, Chung PT, Hoang HT, Nguyen TV, Tanimoto T, Lihana R, Matsushita K, Bi X, Pham TV, Ichimura H. Prevalence of HBV infection among different HIV-risk groups in Hai Phong, Vietnam. J Med Virol 2011;83:399-404. [21264 859] [http://dx.doi.org/10.1002/jmv. 21978] 10 Alavian SM, Hajariazdeh B, Ahmadzad Asl M, Kabir A, Bagheri Lankarani K. Hepatitis B Virus Infection in Iran: A Systematic Review. Hepat Mon 2008;8:281-94. 11 Nokhodian Z, Kassaian N, Ataei B, Javadi AA, Shoaei P, Farajzadegan Z, Adibi P. Hepatitis B Markers in Isfahan, Central Iran: A Population- Based Study. Hepat Mon 2009;9:12-6. 12 SeyedAlinaghi SA, Kheirandish P, Karami N, Salem S, Shirzad H, Jahani MR, SeyedAhmadian MR, Valiollahi P, Hosseini M, Mohraz M, McFarland W. High Prevalence of Chronic Hepatitis B Infection among Injection Drug Useres in Iran: The need to Increase Vaccination of Adults at Risk. Acta Med Iran 2010;48:58-60. [21137671] 13 Iser DM, Lewin SR. The pathogenesis of liver disease in the setting of HIV- hepatitis B virus coinfection. Antivir Ther 2009;14:155-64. [19430090] 14 Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD; HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34. [16878047] [http://dx.doi. org/10.1097/01.qai.0000233310.904 84.16] 15 Lewden C, Salmon D, Morlat P, Bévilacqua S, Jougla E, Bonnet F, Héripret L, Costagliola D, May T, Chêne G; Mortality 2000 study group. Causes of death among human immunodeficiency virus (HIV)- infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34:121-30. [15561752] [http://dx.doi. org/10.1093/ije/dyh307] 16 Lacombe K, Bottero J, Lemoine M, Boyd A, Girard PM. HIV/hepatitis B virus co-infection: current challenges and new strategies. J Antimicrob Chemother 2010;65:10-7. [199009 50] [http://dx.doi.org/10.1093/jac/ dkp414] 17 Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009;49:S138-45. [1939 9813] [http://dx.doi.org/10.1002/hep. 22883] 18 Harania RS, Karuru J, Nelson M, Stebbing J. HIV, hepatitis B and hepatitis C coinfection in Kenya. AIDS 2008;22:1221-2. [18525268] [http://dx.doi.org/10.1097/QAD.0b01 3e32830162a8] 19 World Health Organization (WHO). WHO/CDS/CSR/LYO/2002:2. Hepatitis B. 20 Azadmanesh K, Mohraz M, Aghakhani A, Edalat R, Jam S, Eslamifar A, Banifazl M, Moradmand-Badie B, Ramezani A. Occult hepatitis B virus infection in HIV-infected patients with isolated hepatitis B core antibody. Intervirology 2008;51:270-4. [18841029] [http:// dx.doi.org/10.1159/000160217] 21 Ramezani A, Banifazl M, Mohraz M, Rasoolinejad M, Aghakhani A. Occult hepatitis B virus infection: A major concern in HIV-infected patients. Hepat Mon 2011;11:7-10. 22 Marion PL. Use of animal models to study hepatitis B virus. Prog Med Virol 1988;35:43-75. [3051133] 23 Hollinger FB, Habibollahi P, Daneshmand A, Alavian SM. Occult Hepatitis B Infection in Chronic Hemodialysis Patients: Current Concepts and Strategy. Hepat Mon 2010;10:199-204. 24 Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1970;1:695-8. [41 90997] [http://dx.doi.org/10.1016/ Epidemiology of HIV/HBV co-infections S0140-6736(70)90926-8] 25 Robinson WS, Lutwick LI. The virus of hepatitis, type B (first of two parts). N Engl J Med 1976;295: 1168-75. [62280] [http://dx.doi.org/ 10.1056/NEJM197611182952105] 26 Jazayeri S, Carman W. Evolution of Hepatitis B Genotype D in the Middle East and South Asia. Hepat Mon 2009;9:9-111. 27 de Franchis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninno E, Rumi MG, Donato MF, Ronchi G. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993;118:191-4. [8417636] 28 Taghavi SA, Tabibi M, Eshraghian A, Keyvani H, Eshraghian H. Prevalence and Clinical Significance of Hepatitis B Basal Core Promoter and Precore Gene Mutations in Southern Iranian Patients. Hepat Mon 2010;10:294-7. 29 Chisari FV, Ferrari C. Hepatitis B virus immunopathology. Springer Semin Immunopathol 1995;17:261- 81. [8571172] [http://dx.doi.org/10. 1007/BF00196169] 30 Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR. Increasing mortality due to end- stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32: 492-7. [11170959] [http://dx.doi.org/ 10.1086/318501] 31 Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Muñoz A, Thomas DL; Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360: 1921-6. [12493258] [http://dx.doi.org/ 10.1016/S0140-6736(02)11913-1] 32 Weber B, Rabenau H, Berger A, Scheuermann EH, Staszewski S, Kreuz W, Scharrer I, Schoeppe W, Doerr HW. Seroprevalence of HCV, HAV, HBV, HDV, HCMV and HIV in high risk groups/Frankfurt a.M., Germany. Zentralbl Bakteriol 1995; 282:102-12. [7734823] 33 Chang JJ, Sirivichayakul S, Avihingsanon A, Thompson AJ, Revill P, Iser D, Slavin J, Buranapraditkun S, Marks P, Matthews G, Cooper DA, Kent SJ, Cameron PU, Sasadeusz J, Desmond P, Locarnini S, Dore GJ, Ruxrungtham K, Lewin SR. Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J Virol 2009;83:7649-58. [19458009] [http:// dx.doi.org/10.1128/JVI.00183-09] 34 Alter MJ. Epidemiology and prevention of hepatitis B. Semin WWW.ircmj.com Vol 13 December 2011 861